Aurinia Pharmaceuticals
AUPH
242 hedge funds and large institutions have $730M invested in Aurinia Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 63 increasing their positions, 90 reducing their positions, and 20 closing their positions.
135% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 20
82% more call options, than puts
Call options by funds: $16.1M | Put options by funds: $8.82M
47% more capital invested
Capital invested by funds: $497M → $730M (+$233M)
11% more funds holding
Funds holding: 219 → 242 (+23)
6.75% more ownership
Funds ownership: 43.43% → 50.17% (+6.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
30% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 90
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$25.1M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$15M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$14.2M |
| 4 |
Two Sigma Investments
New York
|
+$12.9M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$8.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$13.8M |
| 2 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
-$5.57M |
| 3 |
Morgan Stanley
New York
|
-$4.91M |
| 4 |
Lazard Asset Management
New York
|
-$4.84M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$3.59M |
AUPH Hedge Fund Activity: Q3 2025 in Review
242 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q3 2025, worth a combined $730M — up 47% from $497M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new AUPH positions and 20 closed out — a net gain of 27 holders — while 63 added to existing stakes and 90 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $25.1M. The largest seller was Armistice Capital, exiting entirely with an estimated $13.8M sold.
- 242 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q3 2025, up from 219 in Q2 2025.
- Funds reported $730M of Aurinia Pharmaceuticals stock for Q3 2025, up 47% quarter-over-quarter.
- 47 funds opened new Aurinia Pharmaceuticals positions in Q3 2025 and 20 closed out, a net change of +27 holders.
- The largest Aurinia Pharmaceuticals buyer in Q3 2025 was Arrowstreet Capital, an estimated $25.1M added.
- The largest Aurinia Pharmaceuticals seller in Q3 2025 was Armistice Capital, an estimated $13.8M sold.
Based on aggregated 13F filings for Q3 2025.